Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Placebo and Active Comparator Controlled Phase 3a Study

Tamsulosin OCAS 0.8 mg is not superior to tamsulosin MR 0.4 mg and is associated with a higher incidence of AEs. Therefore, 0.4 mg is the recommended dose of tamsulosin OCAS in the treatment of patients with LUTS/BPH. The efficacy of tamsulosin OCAS 0.4 mg is superior to placebo and comparable to tamsulosin MR 0.4 mg with a tendency towards a better efficacy/tolerability ratio than with tamsulosin MR 0.4 mg.